4Q Update: Sophiris Bio Inc (SPHS) Gets A Buy From Maxim

  • Maxim analyst Jason Kolbert was out with a research note on Sophiris Bio Inc (NASDAQ:SPHS), following the company’s fourth-quarter financial results and update on its clinical progress.
  • In the release announcing the results, the company disclosed that it has initiated a Phase 2b clinical study with topsalysin for the focal treatment of localized prostate cancer.
  • Kolbert reiterates a Buy rating on Sophiris, with a price target of $6.00, which represents a potential upside of 113% from where the stock is currently trading.
  • According to TipRanks, Kolbert has a yearly average return of -12.1% and a 32% success rate. Kolbert has a 102.4% average return when recommending SPHS, and is ranked #4475 out of 4554 analysts.

  • Sophiris shares are currently trading at $2.85, down $0.02 or -0.70%.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts